CDTX — Cidara Therapeutics Share News
0.000.00%
Last trade - 00:00- $6.95bn
- $6.53bn
- $1.28m
Cidara Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Cidara Therapeutics Receives $11.14 Million Milestone Payment
Brief: Cidara Therapeutics Announces Approval Of Rezzayo By The MHRA For Treatment Of Invasive Candidiasis In Adults
Cidara rises as UK approves fungal infection treatment
U.S. STOCKS ON THE MOVE-Cidara Therapeutics, Senti Bio, Lumentum Holdings
U.S. STOCKS ON THE MOVE-Newmont Corp, Ansys, Karuna Therapeutics
Cidara rises after EU approves fungal infection treatment
Brief: Cidara Therapeutics Announces European Approval Of Rezzayo® (Rezafungin)
Brief: Cidara Therapeutics Announces Completion Of Enrollment In Phase 3 Restore Trial Of Rezafungin In China
Cidara Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Cidara Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Mundipharma And Cidara Therapeutics Receive Positive CHMP Opinion For Rezafungin For The Treatment Of Invasive Candidiasis In Adults
Cidara Therapeutics rises after EU regulator backs antifungal drug
Brief: Cidara Therapeutics To Host Virtual R&D Day On Its Cloudbreak Development Pipeline On Sept 21
Brief: Cidara Therapeutics Announces Janssen’S Election To Proceed Under Its License Agreement Relating To Novel Drug-FC Conjugates Targeting Influenza
Brief: Cidara Therapeutics Appoints Nicole Davarpanah As Senior VP Of Translational Research & Development
Cidara Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Cidara Therapeutics Q2 revenue USD 7.614 million
Brief: Cidara Therapeutics Provides Update On Rezzayo™ (Rezafungin For Injection)